Cargando…
New targeted treatments for non-small-cell lung cancer – role of nivolumab
Non-small-cell lung cancer (NSCLC) is often diagnosed at an advanced stage of disease, where it is no longer amenable to curative treatment. During the last decades, the survival has only improved significantly for lung cancer patients who have tumors harboring a driver mutation. Therefore, there is...
Autores principales: | Zago, Giulia, Muller, Mirte, van den Heuvel, Michel, Baas, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975160/ https://www.ncbi.nlm.nih.gov/pubmed/27536062 http://dx.doi.org/10.2147/BTT.S87878 |
Ejemplares similares
-
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
por: Schouten, Robert D., et al.
Publicado: (2020) -
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment
por: Otten, Leila S., et al.
Publicado: (2023) -
Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
por: van Delft, Frederik A., et al.
Publicado: (2022) -
Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016) -
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
por: Le, Alexander D, et al.
Publicado: (2017)